drugset / Trial / NCT02291991

Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects

NCT02291991

Phase 1 Completed 10 enrolled Genexine, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, placebo controlled, single dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-E2 in healthy male subjects.

Timeline

Start
2014-11
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-E2 Unknown 8 ug/kg Intravenous

Indications

No indication recorded.